Literature DB >> 22199292

The expression of Ki-67, but not proliferating cell nuclear antigen, predicts poor disease free survival in patients with adenocarcinoma of the lung.

Soichi Oka1, Hidetaka Uramoto, Hidehiko Shimokawa, Takashi Iwanami, Fumihiro Tanaka.   

Abstract

BACKGROUND: Ki-67 expression has been established as a predictive marker for recurrence in breast cancer, and proliferating cell nuclear antigen (PCNA) which is also a proliferation marker, is also herein discussed regarding its role in the prognosis of various types of cancer. However, no useful data are presently available regarding the biological significance of both molecules in lung cancer. PATIENTS AND METHODS: Tumor specimens were collected from 183 consecutive patients who underwent a complete resection for lung adenocarcinoma from 2003 to 2007 in our Department. We analyzed the Ki-67 and PCNA expression levels in primary lung adenocarcinoma by immunohistochemistry.
RESULTS: Positive expression of Ki-67 and PCNA was identified in 41 (22.4%) and 149 (81.4%) patients, respectively. The positive expression of Ki-67 was identified in 14 (50.0%) out of 28 patients and 27 (18.1%) out of 155 patients with and without recurrence, respectively (p<0.001). PCNA expression was not correlated with recurrence. Positive expression of Ki-67 was associated with a poorer disease-free survival according to the survival analysis. A multivariate analysis also demonstrated that Ki-67 expression was independently associated with an increased risk of poor disease-free survival.
CONCLUSION: Ki-67 may be a useful marker for predicting postoperative recurrence in patients with non-small cell lung cancer following complete resection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22199292

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  20 in total

1.  Possible prognostic significance of p53, cyclin D1 and Ki-67 in the second primary malignancy of patients with double primary malignancies.

Authors:  Ming Dong; Hui Wei; Jun-Ming Hou; Shan Gao; De-Zhen Yang; Zhen-Hua Lin; Yong Jia; Xiao-Peng Ren; Mei-Hua Gao
Journal:  Int J Clin Exp Pathol       Date:  2014-06-15

2.  Detecting Hematopoietic Stem Cell Proliferation Using BrdU Incorporation.

Authors:  Katie A Matatall; Claudine S Kadmon; Katherine Y King
Journal:  Methods Mol Biol       Date:  2018

3.  Thymidine kinase 1 is a better prognostic marker than Ki-67 for pT1 adenocarcinoma of the lung.

Authors:  Yan Xu; Biao Liu; Qun-Li Shi; Pei-Lin Huang; Xiao-Jun Zhou; Heng-Hui Ma; Zhen-Feng Lu; Yu Bo; Staffan Eriksson; Ellen He; Sven Skog
Journal:  Int J Clin Exp Med       Date:  2014-08-15

4.  Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT.

Authors:  Bowen Shi; Huimin Lin; Miao Zhang; Wei Lu; Ying Qu; Huan Zhang
Journal:  J Vis Exp       Date:  2018-01-22       Impact factor: 1.355

Review 5.  Recurrence after surgery in patients with NSCLC.

Authors:  Hidetaka Uramoto; Fumihiro Tanaka
Journal:  Transl Lung Cancer Res       Date:  2014-08

6.  18 F-fluorothymidine uptake in follicular lymphoma and error-prone DNA repair.

Authors:  Marielle J Wondergem; Ken Herrmann; Sergei Syrbu; Josée M Zijlstra; Nikie Hoetjes; Otto S Hoekstra; Saskia Agm Cillessen; Laura M Moesbergen; Andreas K Buck; Julie M Vose; Malik E Juweid
Journal:  EJNMMI Res       Date:  2014-01-08       Impact factor: 3.138

7.  Comparison of the value of PCNA and Ki-67 as markers of cell proliferation in ameloblastic tumors.

Authors:  Ronell Bologna-Molina; Adalberto Mosqueda-Taylor; Nelly Molina-Frechero; Ana-Dolores Mori-Estevez; Guillermo Sánchez-Acuña
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2013-03-01

8.  Nuclear LEF1/TCF4 correlate with poor prognosis but not with nuclear β-catenin in cerebral metastasis of lung adenocarcinomas.

Authors:  A Bleckmann; L Siam; F Klemm; E Rietkötter; Chr Wegner; F Kramer; T Beissbarth; C Binder; Chr Stadelmann; T Pukrop
Journal:  Clin Exp Metastasis       Date:  2012-12-08       Impact factor: 5.150

9.  Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.

Authors:  Qun Wang; Yan-Jun Zhong; Jing-Ping Yuan; Li-Hua Shao; Jue Zhang; Li Tang; Shao-Ping Liu; Ya-Ping Hong; Raymond A Firestone; Yan Li
Journal:  J Transl Med       Date:  2013-08-21       Impact factor: 5.531

10.  A comparative study of PCNA and Ki-67 expression in dental follicle, dentigerous cyst, unicystic ameloblastoma and ameloblastoma.

Authors:  Shima Nafarzadeh; Maryam Seyedmajidi; Sina Jafari; Ali Bijani; Ali Rostami-Sarokolaei
Journal:  Int J Mol Cell Med       Date:  2013
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.